US Stock MarketDetailed Quotes

VRTX Vertex Pharmaceuticals

Watchlist
  • 468.130
  • +3.570+0.77%
Close Nov 29 13:00 ET
  • 470.390
  • +2.260+0.48%
Pre 06:28 ET
120.56BMarket Cap-246384P/E (TTM)

Vertex Pharmaceuticals Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
7.99%1.37B
-430.89%-3.75B
45.19%1.31B
-14.35%3.54B
-78.25%234.6M
32.75%1.27B
-0.47%1.13B
-5.89%899.9M
56.23%4.13B
8.38%1.08B
Net income from continuing operations
0.98%1.05B
-492.44%-3.59B
57.13%1.1B
8.96%3.62B
18.31%968.8M
11.26%1.04B
12.98%915.7M
-8.17%699.8M
41.84%3.32B
6.34%818.9M
Operating gains losses
74.19%10.8M
3,075.00%12.7M
521.88%27M
-99.60%600K
-93.33%400K
137.13%6.2M
-99.52%400K
-108.47%-6.4M
971.93%149.1M
149.59%6M
Depreciation and amortization
26.37%53.2M
30.43%54M
37.89%53.5M
22.25%181.3M
53.65%59M
14.71%42.1M
10.99%41.4M
8.08%38.8M
18.07%148.3M
13.61%38.4M
Deferred tax
-6.75%-123.3M
32.73%-118.8M
-39.59%-158.3M
-94.45%-536.5M
-188.45%-131M
36.64%-115.5M
23.02%-176.6M
-821.95%-113.4M
-78.46%-275.9M
453.46%148.1M
Other non cash items
313.33%41.6M
-84.82%-20.7M
-283.84%-36.4M
5.47%-43.2M
-169.61%-32.3M
32.99%-19.5M
81.46%-11.2M
861.54%19.8M
-504.42%-45.7M
672.84%46.4M
Change In working capital
-16.62%157.5M
-198.37%-241.4M
-6.91%129.3M
-177.96%-265.7M
-822.88%-838.9M
133.79%188.9M
-36.04%245.4M
523.48%138.9M
423.95%340.8M
-167.53%-90.9M
-Change in receivables
-749.18%-51.8M
4,758.62%135.1M
-178.01%-251.6M
76.55%-84.1M
50.98%15.4M
94.90%-6.1M
96.55%-2.9M
45.22%-90.5M
-30.54%-358.6M
123.45%10.2M
-Change in inventory
-87.18%-182.5M
-47.25%-107.2M
3.03%-80.1M
-136.73%-322.9M
10.60%-70M
-263.81%-97.5M
-118.62%-72.8M
-4,230.00%-82.6M
-46.98%-136.4M
-190.00%-78.3M
-Change in prepaid assets
117.36%21M
-695.41%-155.9M
114.72%99.2M
-67.19%-545.7M
-58.63%-451.3M
4.87%-121M
-210.73%-19.6M
-31.66%46.2M
-255.56%-326.4M
-1,889.31%-284.5M
-Change in payables and accrued expense
-37.36%236.7M
-54.15%143.2M
10.09%194.2M
-27.92%478.1M
-39.80%-388.5M
4.02%377.9M
-41.16%312.3M
274.52%176.4M
96.65%663.3M
-364.41%-277.9M
-Change in other current liabilities
276.69%134.1M
-1,003.52%-256.6M
87.47%167.6M
-58.13%208.9M
-89.71%55.5M
495.56%35.6M
159.92%28.4M
469.43%89.4M
2,869.64%498.9M
541.62%539.6M
Cash from discontinued investing activities
Operating cash flow
7.99%1.37B
-430.89%-3.75B
45.19%1.31B
-14.35%3.54B
-78.25%234.6M
32.75%1.27B
-0.47%1.13B
-5.89%899.9M
56.23%4.13B
8.38%1.08B
Investing cash flow
Cash flow from continuing investing activities
-195.67%-348M
-52.58%-463.7M
-16.51%-2.14B
-878.42%-3.14B
-604.84%-886.5M
69.36%-117.7M
-394.15%-303.9M
-3,495.29%-1.83B
5.81%-321.1M
231.04%175.6M
Net PPE purchase and sale
-66.75%-67.7M
-15.77%-69M
-62.47%-68.4M
2.10%-200.4M
-72.92%-58.1M
25.09%-40.6M
-11.82%-59.6M
33.81%-42.1M
12.89%-204.7M
45.63%-33.6M
Net intangibles purchase and sale
--0
---7.7M
---180M
---58M
---58M
--0
--0
--0
--0
----
Net business purchase and sale
----
----
----
--0
--0
----
----
----
---295.9M
--0
Net investment purchase and sale
81.32%-14.2M
-73.51%-372M
-5.39%-1.89B
-1,706.30%-2.88B
-483.08%-801.4M
-122.87%-76M
-2,514.63%-214.4M
-14,318.25%-1.79B
269.50%179.5M
389.75%209.2M
Net other investing changes
-636.36%-8.1M
----
----
----
----
---1.1M
----
----
----
----
Cash from discontinued investing activities
Investing cash flow
-195.67%-348M
-52.58%-463.7M
-16.51%-2.14B
-878.42%-3.14B
-604.84%-886.5M
69.36%-117.7M
-394.15%-303.9M
-3,495.29%-1.83B
5.81%-321.1M
231.04%175.6M
Financing cash flow
Cash flow from continuing financing activities
-134.85%-387.5M
-2,172.83%-358.6M
-21.31%-357.5M
-730.43%-562.2M
-398.01%-119.8M
-174.09%-165M
-63.73%17.3M
-208.91%-294.7M
95.42%-67.7M
111.96%40.2M
Net issuance payments of debt
52.21%-5.4M
-24.55%-13.7M
-24.53%-13.2M
47.44%-43.1M
-47.83%-10.2M
77.17%-11.3M
13.39%-11M
17.83%-10.6M
-338.50%-82M
-309.09%-6.9M
Net common stock issuance
-129.96%-391.4M
-1,176.43%-400.8M
-21.81%-364.7M
-280.06%-653.7M
-7,171.43%-152.7M
-254.58%-170.2M
-613.64%-31.4M
-154.81%-299.4M
88.98%-172M
99.43%-2.1M
Proceeds from stock option exercised by employees
-45.45%8.4M
-6.14%55M
19.01%16.9M
-27.75%134.6M
-10.08%46.4M
-57.92%15.4M
-9.01%58.6M
-57.86%14.2M
82.65%186.3M
48.70%51.6M
Net other financing activities
-18.18%900K
-18.18%900K
218.18%3.5M
----
----
57.14%1.1M
175.00%1.1M
-15.38%1.1M
----
----
Cash from discontinued financing activities
Financing cash flow
-134.85%-387.5M
-2,172.83%-358.6M
-21.31%-357.5M
-730.43%-562.2M
-398.01%-119.8M
-174.09%-165M
-63.73%17.3M
-208.91%-294.7M
95.42%-67.7M
111.96%40.2M
Net cash flow
Beginning cash position
-54.78%4.59B
-1.36%9.17B
-1.33%10.37B
54.59%10.51B
21.14%11.12B
16.65%10.15B
22.25%9.3B
54.59%10.51B
13.55%6.8B
46.13%9.18B
Current changes in cash
-35.65%634.3M
-639.74%-4.58B
3.35%-1.19B
-104.45%-166.6M
-159.63%-771.7M
92.86%985.7M
-24.71%847.8M
-251.69%-1.23B
353.69%3.74B
146.61%1.29B
Effect of exchange rate changes
201.33%22.8M
-125.00%-2.5M
-230.00%-15.6M
192.12%26.9M
-32.84%27.4M
41.10%-22.5M
138.61%10M
303.39%12M
-117.91%-29.2M
932.65%40.8M
End cash Position
-52.79%5.25B
-54.78%4.59B
-1.36%9.17B
-1.33%10.37B
-1.33%10.37B
21.14%11.12B
16.65%10.15B
22.25%9.3B
54.59%10.51B
54.59%10.51B
Free cash flow
6.05%1.3B
-456.37%-3.83B
23.36%1.06B
-16.47%3.28B
-88.66%118.5M
36.23%1.23B
-1.08%1.07B
-3.90%857.8M
62.97%3.93B
11.96%1.04B
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
--
--
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022(Q4)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities 7.99%1.37B-430.89%-3.75B45.19%1.31B-14.35%3.54B-78.25%234.6M32.75%1.27B-0.47%1.13B-5.89%899.9M56.23%4.13B8.38%1.08B
Net income from continuing operations 0.98%1.05B-492.44%-3.59B57.13%1.1B8.96%3.62B18.31%968.8M11.26%1.04B12.98%915.7M-8.17%699.8M41.84%3.32B6.34%818.9M
Operating gains losses 74.19%10.8M3,075.00%12.7M521.88%27M-99.60%600K-93.33%400K137.13%6.2M-99.52%400K-108.47%-6.4M971.93%149.1M149.59%6M
Depreciation and amortization 26.37%53.2M30.43%54M37.89%53.5M22.25%181.3M53.65%59M14.71%42.1M10.99%41.4M8.08%38.8M18.07%148.3M13.61%38.4M
Deferred tax -6.75%-123.3M32.73%-118.8M-39.59%-158.3M-94.45%-536.5M-188.45%-131M36.64%-115.5M23.02%-176.6M-821.95%-113.4M-78.46%-275.9M453.46%148.1M
Other non cash items 313.33%41.6M-84.82%-20.7M-283.84%-36.4M5.47%-43.2M-169.61%-32.3M32.99%-19.5M81.46%-11.2M861.54%19.8M-504.42%-45.7M672.84%46.4M
Change In working capital -16.62%157.5M-198.37%-241.4M-6.91%129.3M-177.96%-265.7M-822.88%-838.9M133.79%188.9M-36.04%245.4M523.48%138.9M423.95%340.8M-167.53%-90.9M
-Change in receivables -749.18%-51.8M4,758.62%135.1M-178.01%-251.6M76.55%-84.1M50.98%15.4M94.90%-6.1M96.55%-2.9M45.22%-90.5M-30.54%-358.6M123.45%10.2M
-Change in inventory -87.18%-182.5M-47.25%-107.2M3.03%-80.1M-136.73%-322.9M10.60%-70M-263.81%-97.5M-118.62%-72.8M-4,230.00%-82.6M-46.98%-136.4M-190.00%-78.3M
-Change in prepaid assets 117.36%21M-695.41%-155.9M114.72%99.2M-67.19%-545.7M-58.63%-451.3M4.87%-121M-210.73%-19.6M-31.66%46.2M-255.56%-326.4M-1,889.31%-284.5M
-Change in payables and accrued expense -37.36%236.7M-54.15%143.2M10.09%194.2M-27.92%478.1M-39.80%-388.5M4.02%377.9M-41.16%312.3M274.52%176.4M96.65%663.3M-364.41%-277.9M
-Change in other current liabilities 276.69%134.1M-1,003.52%-256.6M87.47%167.6M-58.13%208.9M-89.71%55.5M495.56%35.6M159.92%28.4M469.43%89.4M2,869.64%498.9M541.62%539.6M
Cash from discontinued investing activities
Operating cash flow 7.99%1.37B-430.89%-3.75B45.19%1.31B-14.35%3.54B-78.25%234.6M32.75%1.27B-0.47%1.13B-5.89%899.9M56.23%4.13B8.38%1.08B
Investing cash flow
Cash flow from continuing investing activities -195.67%-348M-52.58%-463.7M-16.51%-2.14B-878.42%-3.14B-604.84%-886.5M69.36%-117.7M-394.15%-303.9M-3,495.29%-1.83B5.81%-321.1M231.04%175.6M
Net PPE purchase and sale -66.75%-67.7M-15.77%-69M-62.47%-68.4M2.10%-200.4M-72.92%-58.1M25.09%-40.6M-11.82%-59.6M33.81%-42.1M12.89%-204.7M45.63%-33.6M
Net intangibles purchase and sale --0---7.7M---180M---58M---58M--0--0--0--0----
Net business purchase and sale --------------0--0---------------295.9M--0
Net investment purchase and sale 81.32%-14.2M-73.51%-372M-5.39%-1.89B-1,706.30%-2.88B-483.08%-801.4M-122.87%-76M-2,514.63%-214.4M-14,318.25%-1.79B269.50%179.5M389.75%209.2M
Net other investing changes -636.36%-8.1M-------------------1.1M----------------
Cash from discontinued investing activities
Investing cash flow -195.67%-348M-52.58%-463.7M-16.51%-2.14B-878.42%-3.14B-604.84%-886.5M69.36%-117.7M-394.15%-303.9M-3,495.29%-1.83B5.81%-321.1M231.04%175.6M
Financing cash flow
Cash flow from continuing financing activities -134.85%-387.5M-2,172.83%-358.6M-21.31%-357.5M-730.43%-562.2M-398.01%-119.8M-174.09%-165M-63.73%17.3M-208.91%-294.7M95.42%-67.7M111.96%40.2M
Net issuance payments of debt 52.21%-5.4M-24.55%-13.7M-24.53%-13.2M47.44%-43.1M-47.83%-10.2M77.17%-11.3M13.39%-11M17.83%-10.6M-338.50%-82M-309.09%-6.9M
Net common stock issuance -129.96%-391.4M-1,176.43%-400.8M-21.81%-364.7M-280.06%-653.7M-7,171.43%-152.7M-254.58%-170.2M-613.64%-31.4M-154.81%-299.4M88.98%-172M99.43%-2.1M
Proceeds from stock option exercised by employees -45.45%8.4M-6.14%55M19.01%16.9M-27.75%134.6M-10.08%46.4M-57.92%15.4M-9.01%58.6M-57.86%14.2M82.65%186.3M48.70%51.6M
Net other financing activities -18.18%900K-18.18%900K218.18%3.5M--------57.14%1.1M175.00%1.1M-15.38%1.1M--------
Cash from discontinued financing activities
Financing cash flow -134.85%-387.5M-2,172.83%-358.6M-21.31%-357.5M-730.43%-562.2M-398.01%-119.8M-174.09%-165M-63.73%17.3M-208.91%-294.7M95.42%-67.7M111.96%40.2M
Net cash flow
Beginning cash position -54.78%4.59B-1.36%9.17B-1.33%10.37B54.59%10.51B21.14%11.12B16.65%10.15B22.25%9.3B54.59%10.51B13.55%6.8B46.13%9.18B
Current changes in cash -35.65%634.3M-639.74%-4.58B3.35%-1.19B-104.45%-166.6M-159.63%-771.7M92.86%985.7M-24.71%847.8M-251.69%-1.23B353.69%3.74B146.61%1.29B
Effect of exchange rate changes 201.33%22.8M-125.00%-2.5M-230.00%-15.6M192.12%26.9M-32.84%27.4M41.10%-22.5M138.61%10M303.39%12M-117.91%-29.2M932.65%40.8M
End cash Position -52.79%5.25B-54.78%4.59B-1.36%9.17B-1.33%10.37B-1.33%10.37B21.14%11.12B16.65%10.15B22.25%9.3B54.59%10.51B54.59%10.51B
Free cash flow 6.05%1.3B-456.37%-3.83B23.36%1.06B-16.47%3.28B-88.66%118.5M36.23%1.23B-1.08%1.07B-3.90%857.8M62.97%3.93B11.96%1.04B
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ------Unqualified Opinion------------

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Investment Theme Gene Editing
Gene Editing
Intraday+0.54%